Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Office of Research & Development

print icon sign up for VA Research updates

Funded Project Details - FY2021




Project Number:

I01CX001864-01A1
Title: Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.
Principal Investigator:

Elizabeth A. Eklund

Location: Chicago, IL
Congressional District Code: 7
Research Service: Clinical Science R&D
Project Period: April 2019 - March 2023
FY 2021 Funding Amount: $165,000
Total Award Amount
(all years):
$710,000
Abstract: View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER


Excerpt:

Clinical outcomes in chronic myeloid leukemia (CML) were revolutionized by development of imatinib (IM) and later generation tyrosine kinase inhibitors (TKIs) that target the Bcr-abl oncogene. Currently, ~55% patients with newly diagnosed CML achieve a major molecular response to TKI treatment (MMR) and 17% a complete molecular response (CMR). Because CML patients survive many years, there is interest in identifying those who can discontinue treatment. This interest is encouraged by the 30% inci...



Questions about the R&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.